Half of patients who die from prostate cancer have metastases at diagnosis
the ONA take:
According to a new study published in the journal Prostate Cancer & Prostatic Diseases, researchers sought to determine which types of patients die from prostate cancer in the modern era.
The researchers identified 190 men with metastatic castration-resistant prostate cancer (CRPC) treated between 2008 and 2011 and analyzed the characteristics of the 113 patients who died as a result of prostate cancer.
Of the 113 patients, 56% had identifiable metastases at the time of diagnosis. Of those, 67% had bone metastases, 111% had visceral metastases, and 43% had lymph node metastases. The median time to developing CRPC was 16 months and the median overall survival was approximately 5.2 years.
Among patients who died from prostate cancer, 46% of those initially diagnosed with localized disease had T stage ≥3 and 38% had a Gleason score ≥8. Overall, 26% had a Gleason score ≤6 and 64% were classified as having high-risk prostate cancer. The median overall survival was found to be 8.8 years.
The findings suggest that among those who die from prostate cancer, about half have detectable metastases at diagnosis. Therefore, the researchers recommend that more future studies should be conducted in patients with newly diagnosed metastatic prostate cancer.
researchers sought to determine which types of patients die from prostate cancer in the modern era.
The authors used two monthly curated databases of patients with castration–resistant prostate cancer (CRPC) to describe the natural history of patients dying of CaP in the modern era. In the modern era, approximately half of the patients who die from CaP have metastases at diagnosis.
The paradigm of progression from localized disease to metastasis and eventually death is only represented in the other half, although possible initial screening and staging errors ought to be taken into consideration. More efforts are needed to conduct trials in patients with newly diagnosed metastatic CaP.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis
- GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible
- Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Metronomic Chemotherapy: Improved Tumor Blood Supply Leads to Better Treatment
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|